Edward Tenthoff Analyst Performance

Sr Research Analyst at Piper Sandler

Edward Tenthoff is a stock analyst at Piper Sandler focused in the medical sector, covering 56 publicly traded companies. Over the past year, Edward Tenthoff has issued 13 stock ratings, including and buy recommendations. While full access to Edward Tenthoff's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Edward Tenthoff's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

237 Last 10 Years

Buy Recommendations

79.91% 179 Buy Ratings

Companies Covered

56 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	79.9%	179 ratings
Hold	18.3%	41 ratings
Sell	1.8%	4 ratings

Out of 224 total stock ratings issued by Edward Tenthoff at Piper Sandler, the majority (79.9%) have been Buy recommendations, followed by 18.3% Hold and 1.8% Sell.

Best & Worst Calls

• Best Call

  000000.0%

  PTI

  Dec 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  VSAR

  Sep 2017

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	92.9% of companies on NASDAQ	52 companies
OTCMKTS	3.6% of companies on OTCMKTS	2 companies
NYSE	3.6% of companies on NYSE	2 companies

Edward Tenthoff, an analyst at Piper Sandler, currently covers 56 companies listed on NASDAQ, OTCMKTS and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 52 companies	92.9%
	Miscellaneous 2 companies	3.6%
	Energy 1 company	1.8%
	Transportation 1 company	1.8%

Edward Tenthoff of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on and Energy companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 27 companies	48.2%
PHARMACEUTICAL PREPARATIONS 13 companies	23.2%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC 5 companies	8.9%
MED - DRUGS 3 companies	5.4%
Miscellaneous 2 companies	3.6%
BIOTECHNOLOGY 2 companies	3.6%
MED PRODUCTS 1 company	1.8%
MED INSTRUMENTS 1 company	1.8%
SOLAR 1 company	1.8%
TRANS - AIRLINE 1 company	1.8%

Edward Tenthoff's Ratings History at Piper Sandler

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
CAMP CAMP4 Therapeutics	9/15/2025	Lower Price Target	$3.25	$12.00	Overweight	$0.00 00.00% ROI
ALNY Alnylam Pharmaceuticals	8/1/2025	Boost Price Target	$392.24	$449.00	Overweight	$0.00 00.00% ROI
NXTC NextCure	7/15/2025	Set Price Target	$4.85	$15.00	Overweight	$0.00 00.00% ROI
CAPR Capricor Therapeutics	7/11/2025	Reiterated Rating	$7.94	$20.00	Overweight	$0.00 00.00% ROI
INO Inovio Pharmaceuticals	7/9/2025	Initiated Coverage	$1.34	$5.00	Overweight	$0.00 00.00% ROI
CRSP CRISPR Therapeutics	6/27/2025	Reiterated Rating	$47.45	$105.00	Overweight	$0.00 00.00% ROI
BMEA Biomea Fusion	6/3/2025	Initiated Coverage	$1.55	$7.00	Overweight	$0.00 00.00% ROI
FULC Fulcrum Therapeutics	5/29/2025	Reiterated Rating	$6.90	$9.00	Overweight	$0.00 00.00% ROI
ITOS iTeos Therapeutics	5/14/2025	Reiterated Rating	$7.33	$12.00	Overweight	$0.00 00.00% ROI
ARVN Arvinas	5/2/2025	Reiterated Rating	$7.02	$14.00	Overweight	$0.00 00.00% ROI
IPSC Century Therapeutics	3/20/2025	Lower Price Target	$0.54	$2.00	Overweight	$0.00 00.00% ROI
DYN Dyne Therapeutics	2/28/2025	Lower Price Target	$13.17	$48.00	Overweight	$0.00 00.00% ROI
MESO Mesoblast	2/7/2025	Reiterated Rating	$19.85	$24.00	Overweight	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.